AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care

Size: px
Start display at page:

Download "AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT. Committee on Rheumatologic Care"

Transcription

1 AMERICAN COLLEGE OF RHEUMATOLOGY POSITION STATEMENT SUBJECT: PRESENTED BY: FOR DISTRIBUTION TO: Bone Mineral Density Measurement and the Role of Rheumatologists in the Management of Osteoporosis Committee on Rheumatologic Care Members of the American College of Rheumatology Medical Societies Centers for Medicare and Medicaid Services Managed Care Organizations/Third Party Carriers Members of Congress Arthritis Foundation National Osteoporosis Foundation POSITIONS: 1. The American College of Rheumatology (ACR) supports the appropriate use of bone mineral density (BMD) testing for the diagnosis of osteoporosis or low bone mass. This is a critical element in fracture risk assessment. 2. The ACR supports the use of serial BMD testing when appropriate to monitor osteoporosis treatment response or to monitor progression of osteoporosis or low bone mass near treatment thresholds. The frequency of retesting should be determined based upon previous test results, existing literature, and clinical judgment of the rheumatologist. 3. Rheumatologists are among those who are uniquely qualified to read and report BMD tests, and should be reimbursed for their reads (see also the ACR s Diagnostic Imaging Credentialing position statement). 4. In addition to T-scores, BMD test reports should include an individualized clinical summary of osteoporosis risk factors. 5. The ACR concurs with the National Osteoporosis Foundation guidelines on use of BMD measurements in both the diagnosis and interval monitoring of bone mass in the following groups of patients (1): Women 65 years and older, regardless of clinical risk profile. Men aged 70 years and older, regardless of clinical risk profile. Younger postmenopausal women and men aged 50 to 69 years about whom there is concern for fracture based on their clinical risk. Women in the menopausal transition if there is a specific risk factor associated with increased fracture, such as low body weight, prior low-trauma fracture, or high risk medication. Adults who have a fracture after age 50. Anyone being considered for pharmacologic therapy for osteoporosis. Anyone being treated for osteoporosis, to monitor treatment effect. Anyone not receiving therapy in whom evidence of bone loss would lead to treatment. 1 P age

2 Postmenopausal women discontinuing estrogen. 6. Many patients managed by rheumatology providers are at risk of glucocorticoid-induced osteoporosis (GIOP). The ACR supports adequate coverage by government and third-party insurance carriers for BMD testing for GIOP at intervals recommended by ACR guidelines (2): For adults < 40 years of age, BMD testing should be done as soon as possible but minimally within 6 months of the initiation of glucocorticoid treatment if the patient is at high fracture risk because of a history of previous osteoporotic fracture(s) or if the patient has other significant osteoporosis risk factors (e.g. rheumatoid arthritis, malnutrition, significant weight loss or low body weight, hypogonadism, secondary hyperparathyroidism, thyroid disease, family history of hip fracture, smoking, alcohol use at 3 units/day). For adults 40 years of age who continue glucocorticoid treatment and are not treated with an osteoporosis medication beyond calcium and vitamin D, reassessment with BMD testing should be completed every 1 3 years. This reassessment should be performed earlier within this 1 3-year time range for adults age 40 years who are receiving very high doses of glucocorticoids (initial prednisone dose 30 mg/day, cumulative dose >5 grams in the previous year) or those with a history of osteoporotic fracture(s). For adults 40 years old who continue glucocorticoid treatment and are currently treated with an osteoporosis medication in addition to calcium and vitamin D, BMD testing should be completed every 2 3 years during treatment in high-risk patients such as those receiving very high-dose glucocorticoids (initial prednisone dose 30 mg/day, cumulative dose >5 grams in the previous year), a history of osteoporotic fracture occurring after 18 months of treatment with anti-fracture medication (other than calcium and vitamin D), risks for poor medication adherence or absorption, or other significant osteoporosis risk factors. For adults 40 years old who received an osteoporosis treatment in the past but are no longer being treated with an osteoporosis medication other than calcium and vitamin D, BMD testing should be done every 2 3 years. Within this range, reassessment should be conducted earlier in patients receiving higher doses of glucocorticoids and those with a history of fracture or low BMD. For all adults <40 years of age who continue glucocorticoid treatment and are at moderate-to-high fracture risk (history of previous fracture, BMD Z score < -3, received very high-dose prednisone [ 30 mg/day and cumulative dose >5 grams] in the previous year, risks for poor medication adherence or absorption, or multiple osteoporosis risk factors), BMD testing should be done every 2 3 years. 7. The ACR supports adequate coverage for BMD testing by Medicare and other health insurance carriers for the indications listed above. 8. The ACR supports rheumatology providers with an interest in osteoporosis and the care of individuals with osteoporosis through a wide range of initiatives including: Comprehensive basic science and clinical education programs for professionals; Support for osteoporosis research through grants and other services to investigators; Development of clinical practice guidelines for optimal diagnosis and treatment of osteoporosis; Programs to increase public awareness about osteoporosis and access to expert care from rheumatologists; 2 P age

3 Advocacy for osteoporosis research and care with legislators, government agencies and insurers; and, Cooperation with health organizations interested in osteoporosis. BACKGROUND: Osteoporosis is the most common bone disease in humans and represents a major public health concern (3). It is characterized by low bone mass, deterioration of bone tissue, disruption of bone architecture, compromised bone strength, and an increased risk of fracture (1). Osteoporosis is associated with 1.5 million fractures annually in the United States. The annual direct costs of osteoporosis in the U.S. in 2005 were estimated to be $17 billion and projected costs by year 2025 will be $25.3 billion dollars (4). One-year mortality following a hip fracture in seniors is as high as 24% (5). Of the hip fracture survivors, 60% do not regain their pre-fracture level of independence, and 20% are confined to nursing homes for long-term care (2). Thus, early diagnosis of osteoporosis and prevention of fractures are important to preserve not only the lives, but also the functional independence of the large number of people at risk for fragility fractures. The measurement of BMD is vital to detecting osteoporosis and low bone mass, which in turn are important risk factors for fragility fractures (3, 6-8). In fact, fracture risk increases exponentially as BMD decreases (1). BMD measurement is also an integral component of the World Health Organization s absolute fracture risk assessment algorithm tool (9). This algorithm utilizes BMD or body mass index as well as other risk factors to assess an individual s absolute risk of future fragility fractures. The Fracture risk assessment tool is then used in conjunction with ACR and/or National Osteoporosis Foundation guidelines for cost-effective pharmacological intervention (9, 10). Central measurement of BMD using dual energy x-ray absorptiometry (DXA) remains the gold standard for the diagnosis of osteoporosis and low bone mass. Peripheral measurements of BMD are predictive of fracture but are not precise enough for monitoring patients on therapy (1). Serial measurements of BMD are necessary to monitor efficacy of osteoporosis therapy and to monitor patients not on treatment who are near treatment thresholds. The appropriate interval for repeat measurement is a clinical decision based on individual circumstances. Typically, this might be two years after initiation of therapy and then less frequently once therapeutic effect has been established. In the setting of glucocorticoid use or changing risk factors, more frequent testing may be appropriate (11). The World Health Organization s diagnostic classification defines osteoporosis by BMD measured at the hip or spine less than 2.5 standard deviations below peak bone mass (T-score - 2.5). Osteoporosis occurs most frequently in women after menopause, but can also affect men. It is the cause of most fractures in older people and is an important contributor to mortality, physical disability, and medical expense (1). While genetic predisposition, aging, and estrogen deficiency are the most common contributors, severe bone loss may also be caused by a wide variety of medical problems including rheumatoid arthritis and drugs such as glucocorticoids (which are used in the treatment of a wide range of rheumatologic diseases). In these individuals, 3 P age

4 the weakening of bone may occur at a younger age, setting the stage for premature fractures and disability (11). The prevention and treatment of osteoporosis has been made possible by an increase in public and physician awareness, advances in early diagnosis using bone density measurement and improvements in treatment. Rheumatologists specialize in the diagnosis, management, and treatment of musculoskeletal diseases. Not only is osteoporosis an important member of this family of diseases, it also occurs more commonly among individuals with inflammatory and autoimmune conditions (precisely those who are cared for by rheumatologists). For these reasons, expertise in the prevention, diagnosis and management of osteoporosis is an important professional focus of many rheumatologists. Through training and experience, rheumatologists possess several key competencies that allow them to provide expert care for people with osteoporosis, including: Knowledge of osteoporotic disease, reinforced by continuing education in this field; A practice structure that emphasizes detailed analysis of complex medical problems and highly organized and comprehensive management of chronic diseases; Interpretation of bone density measurement which is key to identifying and managing patients with osteoporosis and those at risk for osteoporosis; A focus on rehabilitation of individuals with physically disabling diseases to recover optimal function and quality of life; and Prevention and treatment of glucocorticoid-induced osteoporosis (11). Some rheumatologists devote their careers to expanding and disseminating knowledge about osteoporosis through an emphasis on clinical or basic science research and education. Their efforts enhance the capabilities of other rheumatologists and physicians in general in managing this disease. Arthritis health professionals including nurses, nurse practitioners, physician assistants, physical and occupational therapists, psychologists and social workers work closely with rheumatologists to provide a wide range of essential services for the care and rehabilitation of people with osteoporosis and other rheumatic diseases. The ACR is the professional organization for rheumatologists and arthritis health professionals, and represents a source of leadership and education for rheumatologists throughout the world. REFERENCES 1. Cosman F, de Beur SJ, LeBoff MS, et al. Clinician s guide to prevention and treatment of osteoporosis. Osteoporosis Int. 2014;25: Buckley L, Guyatt G, Fink HA, et al American College of Rheumatology guideline for the prevention and treatment of osteoporosis. Arthritis Rheumatol U.S. Department of Health and Human Services. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville, MD: U.S. Department of Health and Human Services, Office of the Surgeon General, P age

5 4. Burge RT, Dawson-Hughes B, Solomon D, Wong JB, King AB, Tosteson ANA. Incidence and economic burden of osteoporotic fractures in the United States, J Bone Min Res. 2007;22(3): Robbins JA, Biggs ML, Cauley J. Adjusted mortality after hip fracture: From the cardiovascular health study. J Am Geriatr Soc 2006;54(12): Nelson HD, et al. Screening for postmenopausal osteoporosis: a review of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;137: Cummings S, Nevit M, Browner W, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995; 332: De Laet C, Van Hout BA, Burger H, et al. Hip fracture prediction in elderly men and women: validation in the Rotterdam study. J Bone Miner Res 1998; 12: The World Health Organization Fracture Risk Assessment Tool Dawson-Hughes B, Tosteson A, Melton LJ III, et al. Implications of absolute fracture risk assessment for osteoporosis practice guidelines in the USA. Osteoporosis Int Apr;19(4): Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoidinduced osteoporosis. Arthritis Care Res. 2010;62: Approved by Board of Directors: 08/01 08/05 08/08 08/12 8/17 5 P age

Using the FRAX Tool. Osteoporosis Definition

Using the FRAX Tool. Osteoporosis Definition How long will your bones remain standing? Using the FRAX Tool Gary Salzman M.D. Director Banner Good Samaritan/ Hayden VAMC Internal Medicine Geriatric Fellowship Program Phoenix, Arizona Using the FRAX

More information

Osteoporosis/Fracture Prevention

Osteoporosis/Fracture Prevention Osteoporosis/Fracture Prevention NATIONAL GUIDELINE SUMMARY This guideline was developed using an evidence-based methodology by the KP National Osteoporosis/Fracture Prevention Guideline Development Team

More information

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014

Disclosures. Diagnostic Challenges in Osteoporosis: Whom To Treat 9/25/2014 Disclosures Diagnostic Challenges in Osteoporosis: Whom To Treat Ethel S. Siris, MD Columbia University Medical Center New York, NY Consultant on scientific issues for: AgNovos Amgen Eli Lilly Merck Novartis

More information

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster

O. Bruyère M. Fossi B. Zegels L. Leonori M. Hiligsmann A. Neuprez J.-Y. Reginster DOI 10.1007/s00296-012-2460-y ORIGINAL ARTICLE Comparison of the proportion of patients potentially treated with an anti-osteoporotic drug using the current criteria of the Belgian national social security

More information

New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines

New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines New York State County Comparison of Fall-related Hip Fractures of Older Adults and Number of Dual-X-ray Absorptiometry Machines Michael Bauer New York State Department of Health Bureau of Occupational

More information

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey

Fragile Bones and how to recognise them. Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Fragile Bones and how to recognise them Rod Hughes Consultant physician and rheumatologist St Peter s hospital Chertsey Osteoporosis Osteoporosis is a skeletal disorder characterised by compromised bone

More information

Skeletal Manifestations

Skeletal Manifestations Skeletal Manifestations of Metabolic Bone Disease Mishaela R. Rubin, MD February 21, 2008 The Three Ages of Women Gustav Klimt 1905 1 Lecture Outline Osteoporosis epidemiology diagnosis secondary causes

More information

Case Finding and Risk Assessment for Osteoporosis

Case Finding and Risk Assessment for Osteoporosis Case Finding and Risk Assessment for Osteoporosis Patient may present as a fragility fracture or risk fracture Fragility fracture age 50 Clinical risk factors aged 50 Very strong clinical risk factors

More information

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:

They are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see: : assessing the risk of fragility fracture bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly as new

More information

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC

Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment. William D. Leslie, MD MSc FRCPC Module 5 - Speaking of Bones Osteoporosis For Health Professionals: Fracture Risk Assessment William D. Leslie, MD MSc FRCPC Case #1 Age 53: 3 years post-menopause Has always enjoyed excellent health with

More information

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology.

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Etiology. Presenter Disclosure Information. Epidemiology. 12:45 1:30pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn

More information

Osteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance

Osteoporosis: fragility fracture risk. Costing report. Implementing NICE guidance Osteoporosis: fragility fracture risk Costing report Implementing NICE guidance August 2012 NICE clinical guideline 146 1 of 15 This costing report accompanies the clinical guideline: Osteoporosis: assessing

More information

What Is FRAX & How Can I Use It?

What Is FRAX & How Can I Use It? What Is FRAX & How Can I Use It? Jacqueline Osborne PT, DPT Board Certified Geriatric Clinical Specialist Certified Exercise Expert for the Aging Adult Brooks Rehabilitation; Jacksonville, FL Florida Physical

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 9/29/2017 If the member s subscriber contract excludes coverage

More information

Metabolic Bone Disease and the Gastroenterologist

Metabolic Bone Disease and the Gastroenterologist VOLUME 8, ISSUE 3, YEAR 2009 Metabolic Bone Disease and the Gastroenterologist Peter R. McNally, DO, FACP, FACG University Colorado at Denver, School of Medicine, Center for Human Simulation Series Introduction:

More information

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist

Use of DXA / Bone Density in the Care of Your Patients. Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Use of DXA / Bone Density in the Care of Your Patients Brenda Lee Holbert, M.D. Associate Professor Senior Staff Radiologist Important Websites Resources for Clinicians and Patients www.nof.org www.iofbonehealth.org

More information

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK

nogg Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK nogg NATIONAL OSTEOPOROSIS GUIDELINE GROUP Guideline for the diagnosis and management of osteoporosis in postmenopausal women and men from the age of 50 years in the UK Produced by J Compston, A Cooper,

More information

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio

Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio Osteoporosis 1 Nutritional Aspects of Osteoporosis Care and Treatment Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, Ohio 1) Objectives: a) To understand bone growth and development

More information

Discovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future.

Discovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future. Discovering prior fractures in your postmenopausal patient may be the LINK to reducing her fragility fracture* risk in the future. *A fragility fracture is defined as a fracture caused by minimal trauma,

More information

Bone Mineral Density Studies in Adult Populations

Bone Mineral Density Studies in Adult Populations Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician

More information

International Journal of Health Sciences and Research ISSN:

International Journal of Health Sciences and Research  ISSN: International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article Osteoporosis- Do We Need to Think Beyond Bone Mineral Density? Dr Preeti Soni 1, Dr Shipra

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy SUBJECT: - Forteo (teriparatide), Prolia (denosumab), Tymlos (abaloparatide), Boniva injection (Ibandronate) POLICY NUMBER: Pharmacy-35 EFFECTIVE DATE: 9/07 LAST REVIEW DATE: 10/15/2018 If the member s

More information

IEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan

IEHP UM Subcommittee Approved Authorization Guidelines DEXA Scan Policy: IEHP UM Subcommittee Approved Authorization Guidelines IEHP considers bone mineral density testing using DEXA medically necessary for members who meet any of the following criteria: Women aged

More information

An audit of osteoporotic patients in an Australian general practice

An audit of osteoporotic patients in an Australian general practice professional Darren Parker An audit of osteoporotic patients in an Australian general practice Background Osteoporosis is a major contributor to morbidity and mortality in Australia, and is predicted to

More information

ASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction

ASJ. How Many High Risk Korean Patients with Osteopenia Could Overlook Treatment Eligibility? Asian Spine Journal. Introduction Asian Spine Journal Asian Spine Clinical Journal Study Asian Spine J 2014;8(6):729-734 High http://dx.doi.org/10.4184/asj.2014.8.6.729 risk patients with osteopenia How Many High Risk Korean Patients with

More information

Osteoporosis: A Tale of 3 Task Forces!

Osteoporosis: A Tale of 3 Task Forces! Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker

More information

Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States

Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States 478826JMHXXX10.1177/1557988313478826 American Journal of Men s HealthLim et al. Article Screening for Osteoporosis in Men Aged 70 Years and Older in a Primary Care Setting in the United States American

More information

SCHEDULE 2 THE SERVICES. A. Service Specifications

SCHEDULE 2 THE SERVICES. A. Service Specifications SCHEDULE 2 THE SERVICES A. Service Specifications Service Specification No. 04/MSKT/0013 Service PAN DORSET FRACTURE LIAISON SERVICE Commissioner Lead CCP for Musculoskeletal & Trauma Provider Lead Deputy

More information

Osteoporosis challenges

Osteoporosis challenges Osteoporosis challenges Osteoporosis challenges Who should have a fracture risk assessment? Who to treat? Drugs, holidays and unusual adverse effects Fracture liaison service? The size of the problem 1

More information

Corporate Medical Policy

Corporate Medical Policy Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: bone_mineral_density_studies 12/1996 9/2017 9/2018 9/2017 Description of Procedure or Service Bone density

More information

1

1 www.osteoporosis.ca 1 2 Overview of the Presentation Osteoporosis: An Overview Bone Basics Diagnosis of Osteoporosis Drug Therapies Risk Reduction Living with Osteoporosis 3 What is Osteoporosis? Osteoporosis:

More information

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview

8/6/2018. Glucocorticoid induced osteoporosis: overlooked and undertreated? Disclosure. Objectives. Overview Disclosure Glucocorticoid induced osteoporosis: overlooked and undertreated? I have no financial disclosure relevant to this presentation Tasma Harindhanavudhi, MD Division of Diabetes and Endocrinology

More information

To understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis.

To understand bone growth and development across the lifespan. To develop a better understanding of osteoporosis. Nutrition Aspects of Osteoporosis Care and Treatment t Cynthia Smith, FNP-BC, RN, MSN, CCD Pars Osteoporosis Clinic, Belpre, OH. Objectives To understand bone growth and development across the lifespan.

More information

LOVE YOUR BONES Protect your future

LOVE YOUR BONES Protect your future www.worldosteoporosisday.org LOVE YOUR BONES Protect your future Know your risk for osteoporosis www.iofbonehealth.org Osteoporosis is a problem worldwide, and in many countries, up to one in three women

More information

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm

Interpreting DEXA Scan and. the New Fracture Risk. Assessment. Algorithm Interpreting DEXA Scan and the New Fracture Risk Assessment Algorithm Prof. Samir Elbadawy *Osteoporosis affect 30%-40% of women in western countries and almost 15% of men after the age of 50 years. Osteoporosis

More information

Helpful information about bone health & osteoporosis Patient Resource

Helpful information about bone health & osteoporosis Patient Resource Helpful information about bone health & osteoporosis Patient Resource Every year In the United States, 2.5 million fractures occur due to osteoporosis. Out of these, 330,000 are hip fractures, and half

More information

Osteoporosis: A Tale of 3 Task Forces!

Osteoporosis: A Tale of 3 Task Forces! Osteoporosis: A Tale of 3 Task Forces! Robert A. Adler, MD McGuire Veterans Affairs Medical Center Virginia Commonwealth University Richmond, Virginia, USA Disclosures The opinions are those of the speaker

More information

Defining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool

Defining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool Marshall University Marshall Digital Scholar Orthopaedics Faculty Research Fall 9-2011 Defining Bone Health and Fracture Risk in West Virginia: The World Health Organization FRAX Assessment Tool Franklin

More information

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008

Bone Mass Measurement BONE MASS MEASUREMENT HS-042. Policy Number: HS-042. Original Effective Date: 8/25/2008 Easy Choice Health Plan, Inc. Harmony Health Plan of Illinois, Inc. Missouri Care, Inc. Ohana Health Plan, a plan offered by WellCare Health Insurance of Arizona, Inc. WellCare Health Insurance of Illinois,

More information

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING

Objectives: What is Osteoporosis 10/8/2015. Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING Bone Health/ Osteoporosis: BASICS OF SCREENING, INTERPRETING, AND TREATING TIFFANY PAUL, APN, CNP, CCD Objectives: Review the diagnosis of Osteoporosis Describe the basics of a bone density exam Identify

More information

Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC

Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Management of Osteoporosis : What Do the Guidelines Say? Robert D. Blank, MD, PhD Endocrinology, U of Wisconsin GRECC Service, Middleton VAMC Learning Goals Review guidelines for osteoporosis Consider

More information

Clinical Appropriateness Guidelines: Advanced Imaging

Clinical Appropriateness Guidelines: Advanced Imaging Clinical Appropriateness Guidelines: Advanced Imaging Appropriate Use Criteria: Quantitative CT (QCT) Bone Mineral Densitometry Effective Date: September 5, 2017 Proprietary Date of Origin: 05/21/2007

More information

Forteo (teriparatide) Prior Authorization Program Summary

Forteo (teriparatide) Prior Authorization Program Summary Forteo (teriparatide) Prior Authorization Program Summary FDA APPROVED INDICATIONS DOSAGE 1 FDA Indication 1 : Forteo (teriparatide) is indicated for: the treatment of postmenopausal women with osteoporosis

More information

AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents

AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents AETNA BETTER HEALTH Prior Authorization guideline for Injectable Osteoporosis Agents Injectable Osteoporosis Agents Forteo (teriparatide); zoledronic acid Prolia (denosumab)] Authorization guidelines For

More information

Bone mineral density testing: Is a T score enough to determine the screening interval?

Bone mineral density testing: Is a T score enough to determine the screening interval? Interpreting Key Trials CME CREDIT EDUCATIONAL OBJECTIVE: Readers will measure bone mineral density at reasonable intervals in their older postmenopausal patients Krupa B. Doshi, MD, CCD Department of

More information

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information.

Learning Objectives. Controversies in Osteoporosis Prevention and Management. Definition. Presenter Disclosure Information. 4 4:45 pm Controversies in Osteoporosis Prevention and Management SPEAKER Carolyn Crandall, MD, MS Presenter Disclosure Information The following relationships exist related to this presentation: Carolyn

More information

Make your. first break. your last.

Make your. first break. your last. www.iofbonehealth.org Make your first break your last WHAT IS OSTEOPOROSIS? Osteoporosis is a disease in which bones become more fragile and weak, leading to an increased risk of fractures (broken bones).

More information

BMD: A Continuum of Risk WHO Bone Density Criteria

BMD: A Continuum of Risk WHO Bone Density Criteria Pathogenesis of Osteoporosis Osteoporosis Diagnosis: BMD, FRAX and Assessment of Secondary Osteoporosis AGING MENOPAUSE OTHER RISK FACTORS RESORPTION > FORMATION Bone Loss LOW PEAK BONE MASS Steven T Harris

More information

Management of postmenopausal osteoporosis

Management of postmenopausal osteoporosis Management of postmenopausal osteoporosis Yeap SS, Hew FL, Chan SP, on behalf of the Malaysian Osteoporosis Society Committee Working Group for the Clinical Guidance on the Management of Osteoporosis,

More information

Osteoporosis. Treatment of a Silently Developing Disease

Osteoporosis. Treatment of a Silently Developing Disease Osteoporosis Treatment of a Silently Developing Disease Marc K. Drezner, MD Senior Associate Dean Emeritus Professor of Medicine Emeritus University of Wisconsin-Madison Auditorium The Forest at Duke October

More information

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines

An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines Osteoporos Int (2006) 17: 1111 1115 DOI 10.1007/s00198-006-0101-6 SHORT COMMUNICATION An audit of bone densitometry practice with reference to ISCD, IOF and NOF guidelines R. Baddoura. H. Awada. J. Okais.

More information

Osteoporosis. Overview

Osteoporosis. Overview v2 Osteoporosis Overview Osteoporosis is defined as compromised bone strength that increases risk of fracture (NIH Consensus Conference, 2000). Bone strength is characterized by bone mineral density (BMD)

More information

Identification, Diagnosis, and Prevention of Osteoporosis

Identification, Diagnosis, and Prevention of Osteoporosis n reports n Identification, Diagnosis, and Prevention of Osteoporosis Jeffrey P. Levine, MD, MPH Underdiagnosis and Undertreatment Osteoporosis continues to be a growing problem in the United States, due

More information

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK

Osteoporosis. Open Access. John A. Kanis. Diseases, University of Sheffield, UK Journal of Medical Sciences (2010); 3(3): 00-00 Review Article Osteoporosis Open Access John A. Kanis WHO Collaborating Centre for Metabolic Bone Diseases, University of Sheffield, UK incorporated into

More information

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis

Osteoporosis. Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective. Old Definition of Osteoporosis Current Trend in Osteoporosis Management for Elderly in HK- Medical Perspective Dr Dicky T.K. Choy Physician Jockey Club Centre for Osteoporosis Care and Control, CUHK Osteoporosis Global public health

More information

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only. INJECTABLE OSTEOPOSIS AGENTS SUBJECT Pharmacologic Agents: Bisphosphonates: Boniva IV (ibandronate) Reclast (zoledronic

More information

Current and Emerging Strategies for Osteoporosis

Current and Emerging Strategies for Osteoporosis Current and Emerging Strategies for Osteoporosis I have nothing to disclose. Anne Schafer, MD Assistant Professor of Medicine Division of Endocrinology & Metabolism December 12, 2014 Outline Osteoporosis

More information

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018

Osteoporosis Treatment Overview. Colton Larson RFUMS October 26, 2018 Osteoporosis Treatment Overview Colton Larson RFUMS October 26, 2018 Burden of Disease Most common bone disease 9.9 million Americans + 43.1 million Americans have low bone mineral density (BMD) Stealthy

More information

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017

Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Kaiser Permanente National CLINICAL PRACTICE GUIDELINES Osteoporosis/Fracture Prevention Clinician Guide SEPTEMBER 2017 Introduction This Clinician Guide was developed to assist Primary Care physicians

More information

nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised

nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin NICE provided the content for this booklet which is independent of any company or product advertised nice bulletin Welcome In August 2012, the National Institute for Health and Clinical Excellence

More information

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C

Healthy Bones: Osteoporosis Management. Laurel Short, MSN, FNP-C Healthy Bones: Osteoporosis Management Laurel Short, MSN, FNP-C Disclosure I have no current affiliation or financial interest with any grantor or commercial interests that may have direct interest in

More information

Bone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure?

Bone Densitometry. What is a Bone Density Scan (DXA)? What are some common uses of the procedure? Scan for mobile link. Bone Densitometry What is a Bone Density Scan (DXA)? Bone density scanning, also called dual-energy x-ray absorptiometry (DXA) or bone densitometry, is an enhanced form of x-ray technology

More information

New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS

New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS New 2010 Osteoporosis Guidelines: What you and your health provider need to know QUESTIONS&ANSWERS Wednesday, December 1, 2010 1:00 p.m. to 2:00 p.m. ET 1. I m 55 years old. I ve been taking Fosavance

More information

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS

Osteoporosis: An Overview. Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Osteoporosis: An Overview Carolyn J. Crandall, MD, MS Professor of Medicine David Geffen School of Medicine at UCLA Objectives Review osteoporosis

More information

Advanced medicine conference. Monday 20 Tuesday 21 June 2016

Advanced medicine conference. Monday 20 Tuesday 21 June 2016 Advanced medicine conference Monday 20 Tuesday 21 June 2016 Osteoporosis: recent advances in risk assessment and management Juliet Compston Emeritus Professor of Bone Medicine Cambridge Biomedical Campus

More information

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist

Prevalence of Osteoporosis 5/3/2017. Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Rhiannon Anderson, PA-C, FLS Linda Mitchell, PA-C, FLS, DEXA Specialist Prevalence of Osteoporosis 1.5 million fractures annually in the U.S. Overall lifetime risk for an osteoporotic fracture is about

More information

Bone. Disease. Cartilage. Strategies for Longevity. Joint Health

Bone. Disease. Cartilage. Strategies for Longevity. Joint Health Bone Strategies for Longevity Disease Cartilage Joint Health Introduction Bones adapt using a very simple principle Use it or lose it Like muscle, bone is modified based on the strain it must with stand.

More information

OSTEOPOROSIS: PREVENTION AND MANAGEMENT

OSTEOPOROSIS: PREVENTION AND MANAGEMENT OSTEOPOROSIS: OVERVIEW OSTEOPOROSIS: PREVENTION AND MANAGEMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Key Risk factors Screening and Monitoring

More information

JMSCR Vol 04 Issue 12 Page December 2016

JMSCR Vol 04 Issue 12 Page December 2016 www.jmscr.igmpublication.org Impact Factor 5.244 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v4i12.27 The Prevalence of Osteoporosis and Osteopenia

More information

New Developments in Osteoporosis: Screening, Prevention and Treatment

New Developments in Osteoporosis: Screening, Prevention and Treatment Osteoporosis: Overview New Developments in Osteoporosis: Screening, Prevention and Treatment Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF Definitions Risk factors

More information

Osteoporosis Physician Performance Measurement Set. October 2006

Osteoporosis Physician Performance Measurement Set. October 2006 American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium

More information

Top: Healthy Vertebrae Above: Osteoporotic bone

Top: Healthy Vertebrae Above: Osteoporotic bone Top: Healthy Vertebrae Above: Osteoporotic bone 2 OSTEOPOROSIS IS A DISEASE OF THE BONES, WHICH LEADS TO AN INCREASED RISK OF FRACTURE. IN OSTEOPOROSIS, THE DENSITY AND QUALITY OF BONE ARE REDUCED. THE

More information

Catch the HEDIS Buzz!

Catch the HEDIS Buzz! Catch the HEDIS Buzz! Focus Area: Osteoporosis Management in Women Who Had a Fracture Date: October 2014 HEDIS Performance Score In 2013, Humana At Home associates did a great job of promoting Osteoporosis

More information

Osteoporosis: Who, What, When, Why, and How

Osteoporosis: Who, What, When, Why, and How Osteoporosis: Who, What, When, Why, and How Doris J. Uh, PharmD, AE-C Pharm 445 September 20, 2005 Objectives define osteoporosis (what) determine high risk groups (who, when) review modifiable, non-modifiable

More information

Summary. Background. Diagnosis

Summary. Background. Diagnosis March 2009 Management of post-menopausal osteoporosis This bulletin focuses on the pharmacological management of patients with post-menopausal osteoporosis both those with clinically evident disease (e.g.

More information

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT

NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT NEW DEVELOPMENTS IN OSTEOPOROSIS: SCREENING, PREVENTION AND TREATMENT Judith Walsh, MD, MPH Departments of Medicine and Epidemiology and Biostatistics UCSF OSTEOPOROSIS: OVERVIEW Definitions Risk factors

More information

Pharmacy Management Drug Policy

Pharmacy Management Drug Policy Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines

More information

Submission to the National Institute for Clinical Excellence on

Submission to the National Institute for Clinical Excellence on Submission to the National Institute for Clinical Excellence on Strontium ranelate for the prevention of osteoporotic fractures in postmenopausal women with osteoporosis by The Society for Endocrinology

More information

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women

Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Costing statement: Denosumab for the prevention of osteoporotic fractures in postmenopausal women Resource impact The guidance Denosumab for the prevention of osteoporotic fractures in postmenopausal women

More information

Beyond the T-score: New Thinking in Osteoporosis 2

Beyond the T-score: New Thinking in Osteoporosis 2 Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/clinicians-roundtable/beyond-the-t-score-new-thinking-in-osteoporosis-

More information

Bone Density Measurement in Women

Bone Density Measurement in Women Bone Density Measurement in Women Revised 2005 Scope This guideline defines the medical necessity of bone mineral density (BMD) measurement using dualenergy x-ray absorptiometry (DXA or DEXA), and applies

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Reclast, Zometa) Reference Number: CP.PHAR.59 Effective Date: 03.11 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder

More information

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009

Osteoporosis Physician Performance Measurement Set. October 2006 Coding Reviewed and Updated November 2009 American Academy of Family Physicians/American Academy of Orthopaedic Surgeons/American Association of Clinical Endocrinologists/American College of Rheumatology/The Endocrine Society/Physician Consortium

More information

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11.

NIH Public Access Author Manuscript Endocr Pract. Author manuscript; available in PMC 2014 May 11. NIH Public Access Author Manuscript Published in final edited form as: Endocr Pract. 2013 ; 19(5): 780 784. doi:10.4158/ep12416.or. FRAX Prediction Without BMD for Assessment of Osteoporotic Fracture Risk

More information

Men and Osteoporosis So you think that it can t happen to you

Men and Osteoporosis So you think that it can t happen to you Men and Osteoporosis So you think that it can t happen to you Jonathan D. Adachi MD, FRCPC Alliance for Better Bone Health Chair in Rheumatology Professor, Department of Medicine Michael G. DeGroote School

More information

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk

Dr Tuan V NGUYEN. Mapping Translational Research into Individualised Prognosis of Fracture Risk Dr Tuan V NGUYEN Bone and Mineral Research Program, Garvan Institute of Medical Research, Sydney NSW Mapping Translational Research into Individualised Prognosis of Fracture Risk From the age of 60, one

More information

A JOINT INITIATIVE FOR FRACTURE PREVENTION. Know Your Bones Community Risk Report October 2018

A JOINT INITIATIVE FOR FRACTURE PREVENTION. Know Your Bones Community Risk Report October 2018 A JOINT INITIATIVE FOR FRACTURE PREVENTION Forewords Greg Lyubomirsky CEO Osteoporosis Australia 1 Know Your Bones was developed to help Australians understand their risk of poor bone health and discuss

More information

Proposed Retirement of Existing Measure for HEDIS 1 : Osteoporosis Testing in Older Women (OTO)

Proposed Retirement of Existing Measure for HEDIS 1 : Osteoporosis Testing in Older Women (OTO) Proposed Retirement of Existing Measure for HEDIS 1 : Osteoporosis Testing in Older Women (OTO) NCQA seeks comments on the proposed retirement of the HEDIS health plan measure Osteoporosis Testing in Older

More information

Factors associated with diagnosis and treatment of osteoporosis in older adults

Factors associated with diagnosis and treatment of osteoporosis in older adults Osteoporos Int (2009) 20:1963 1967 DOI 10.1007/s00198-008-0831-8 SHORT COMMUNICATION Factors associated with diagnosis and treatment of osteoporosis in older adults S. Nayak & M. S. Roberts & S. L. Greenspan

More information

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS

CASE 1 WHY IS IT IMPORTANT TO TREAT? FACTS CONCERNS 4:30-5:15pm Ask the Expert: Osteoporosis SPEAKERS Silvina Levis, MD OSTEOPOROSIS - FACTS 1:3 older women and 1:5 older men will have a fragility fracture after age 50 After 3 years of treatment, depending

More information

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases

Fractures: Epidemiology and Risk Factors. July 2012 CME (35 minutes) 7/24/ July12 1. Osteoporotic fractures: Comparison with other diseases Financial Disclosures Fractures: Epidemiology and Risk Factors Research grants, speaking or consulting: Amgen, Lilly, Merck, Novartis, Radius Dennis M. Black, PhD Department of Epidemiology and Biostatistics

More information

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment

FRAX Based Lebanese Osteoporosis Guidelines Second Update for Lebanese Guidelines for Osteoporosis Assessment and Treatment These guidelines are endorsed by the following Lebanese Scientific Societies and Associations: Lebanese Society of Endocrinology Diabetes and Lipids, Lebanese Society of Rheumatology, Lebanese Society

More information

Tymlos (abaloparatide)

Tymlos (abaloparatide) Tymlos (abaloparatide) Policy Number: 5.01.638 Last Review: 11/2018 Origination: 10/2017 Next Review: 11/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for Tymlos

More information

Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic

Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic Dan Med J 1/12 December 2014 danish medical JOURNAL 1 Choice of osteoporosis guideline has important implications for the treatment decision in elderly women referred to a fall clinic Katja Thomsen 1,

More information

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck

Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck Disclosures Fractures: A. Schwartz Epidemiology and Risk Factors Consulting: Merck Ann V. Schwartz, PhD Department of Epidemiology and Biostatistics UCSF Outline Fracture incidence and impact of fractures

More information

Learning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis

Learning Objectives. ! Students will become familiar with the 3 treatment solutions for osteoporosis. ! Students should be able to define osteoporosis Learning Objectives! Students should be able to define osteoporosis! Students should be able to identify some risk factors of osteoporosis! Students should be able to identify some of the people in the

More information

Coordinator of Post Professional Programs Texas Woman's University 1

Coordinator of Post Professional Programs Texas Woman's University 1 OSTEOPOROSIS Update 2007-2008 April 26, 2008 How much of our BMD is under our control (vs. genetics)? 1 2 Genetic effects on bone loss: longitudinal twin study (Makovey, 2007) Peak BMD is under genetic

More information

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi

DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi DXA When to order? How to interpret? Dr Nikhil Tandon Department of Endocrinology and Metabolism All India Institute of Medical Sciences New Delhi Clinical Utility of Bone Densitometry Diagnosis (DXA)

More information

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4.

[If no, skip to question 10.] Y N. 2. Does the member have a diagnosis of Paget s disease of bone? Y N. [If no, skip to question 4. Pharmacy Prior Authorization AETA BETTER HEALTH EW JERSE (MEDICAID) Zoledronic Acid (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information,

More information